April 02, 2025

Accelerated Onset of Aging-Related Diseases in Childhood Cancer Survivors?

In a study reported in JAMA Oncology, Yeh et al found evidence of accelerated aging in survivors of childhood cancers through the observed increased risk and early onset of age-related diseases.

The ASCO Post

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 27, 2025

Trends in Spironolactone Prescribing Among Young Women

A cohort study of 38 million insured females aged 12 to 40 years found a marked increase in spironolactone prescriptions, most commonly for acne and other androgen-related conditions.

Conexiant

March 27, 2025

FDA Approves First Hyperphagia Drug for PWS

FDA approves Vykat XR as first treatment for hyperphagia in patients with Prader-Willi syndrome; decision follows extended review and long-term efficacy data.

Reuters

March 24, 2025

Longer Breastfeeding Duration Linked to Fewer Developmental Delays in Large Study

Children breastfed for 6+ months showed 27% lower odds of developmental delays and neurodevelopmental conditions in comprehensive Israeli analysis of 570,000+ children, with sibling comparisons confirming protective effects.

Conexiant

March 19, 2025

Medical Oddities: Brain Implants Bugged by Bacteria

Bacteria in the brain, words for longevity, and a fishy fix for kindness—this week in medical oddities.

Conexiant

March 19, 2025

Study: Sex Differences in Physician Suicide

Researchers found that female physicians had a significantly higher suicide risk than female nonphysicians.

Conexiant

March 18, 2025

FDA Approves First Liquid Losartan Formulation

FDA approves Arbli (TM), the first ready-to-use losartan oral suspension for hypertension, stroke risk reduction, and diabetic nephropathy.

Conexiant